# Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

> **NCT04706598** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 25 (estimated)

## Conditions studied

- Urinary Bladder Neoplasms
- Immunotherapy

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04706598
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-09
- **Primary completion:** 2024-07-11
- **Final completion:** 2024-12
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2024-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04706598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04706598, "Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04706598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*